Hematology Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
Int J Mol Sci. 2021 Oct 20;22(21):11343. doi: 10.3390/ijms222111343.
Current cytoreductive and antithrombotic strategies in MPNs are mostly based on cell counts and on patient's demographic and clinical history. Despite the numerous studies conducted on platelet function and on the role of plasma factors, an accurate and reliable method to dynamically quantify the hypercoagulability states of these conditions is not yet part of clinical practice. Starting from our experience, and after having sifted through the literature, we propose an in-depth narrative report on the contribution of the clonal platelets of MPNs-rich in tissue factor (TF)-in promoting a perpetual procoagulant mechanism. The whole process results in an unbalanced generation of thrombin and is self-maintained by Protease Activated Receptors (PARs). We chose to define this model as a "circulating wound", as it indisputably links the coagulation, inflammation, and fibrotic progression of the disease, in analogy with what happens in some solid tumours. The platelet contribution to thrombin generation results in triggering a vicious circle supported by the PARs/TGF-beta axis. PAR antagonists could therefore be a good option for target therapy, both to contain the risk of vascular events and to slow the progression of the disease towards end-stage forms. Both the new and old strategies, however, will require tools capable of measuring procoagulant or prohaemorrhagic states in a more extensive and dynamic way to favour a less empirical management of MPNs and their potential clinical complications.
目前,骨髓增殖性肿瘤(MPN)的细胞减灭和抗血栓策略主要基于细胞计数以及患者的人口统计学和临床病史。尽管已经进行了许多关于血小板功能和血浆因子作用的研究,但一种准确、可靠的方法来动态量化这些疾病的高凝状态尚未成为临床实践的一部分。基于我们的经验,并在筛选文献后,我们提出了一篇深入的叙述性报告,探讨了富含组织因子(TF)的 MPN 克隆血小板在促进持久促凝机制中的作用。整个过程导致凝血酶的不平衡产生,并通过蛋白酶激活受体(PARs)自我维持。我们选择将这个模型定义为“循环性伤口”,因为它不可争辩地将疾病的凝血、炎症和纤维化进展联系在一起,类似于某些实体瘤中发生的情况。血小板对凝血酶生成的贡献导致了一个恶性循环,这个循环得到了 PARs/TGF-β轴的支持。因此,PAR 拮抗剂可能是靶向治疗的一个很好的选择,既可以控制血管事件的风险,又可以减缓疾病向终末期形式的进展。然而,无论是新策略还是旧策略,都需要能够更广泛、更动态地测量促凝或促出血状态的工具,以促进对 MPN 及其潜在临床并发症的管理更加经验化。